Solid cash position of €13.5 million
and significant scientific advances
Key highlights in the first half-year of 2018: primary objective met in the first results of TARGET PHASE II study, strategic partnership with the University of North Texas Health Science Center and launch of PHASE I study of repeated and increasing doses with
Results of TANGO PHASE III study with CER-001 with HDL deficiency patients, and results of PHASE I with CER 209, by the end of 2018.
Toulouse, FRANCE, Lakeland, UNITED-STATES, September 10, 2018, 7.00 am cest – CERENIS Therapeutics (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular and metabolic diseases, as well as new HDL-based vectors for targeted drug delivery in the field of oncology, today announces its first half-year 2018 financial results, and takes stock of its clinical advances.
Please find the complete press release here.